期刊文献+

微生态制剂联合标准三联疗法根除幽门螺杆菌感染Meta分析 被引量:6

Meta-analysis: the effect of probiotics supplement on standard triple therapy for Helicobacter pylori eradication
原文传递
导出
摘要 目的系统评价微生态制剂联合标准三联疗法能否提高H.pylori根除率,减少根除过程中的不良反应。方法从常用电子数据库检索标准三联疗法联合与未联合微生态制剂根除H.pylori的随机对照临床试验,Meta分析各项研究的根除率和不良反应发生率的合并OR值,以漏斗图检测发表偏倚。结果共15项随机临床试验符合纳入标准。三联疗法联合与未联合微生态制剂,根除率分别为79.7%(95%CI:77.1%~82.3%)和69.5%(95%CI:66.5%~72.5%),合并OR值为1.75(95%CI:1.40~2.18),总不良反应发生率分别为27.7%(95%CI:24.5%~30.9%)和53.0%(95%CI:49.4%~56.6%),合并OR值为0.35(95%CI:0.21~0.60)。结论微生态制剂联合标准三联疗法可显著提高H.pylori根除率,降低根除过程中的不良反应发生率。 Objective To systematically evaluate the effect of the probiotics and standard triple therapy on the eradication of H.pylori and the side-effects of anti-H.pylori treatment.Method Frequently used electronic databases were searched for all the randomized placebo controlled clinical trials of standard triple therapies with and/or without combination of probiotics for treatment of H.pylori.The summary odds ratio(OR) of H.pylori eradication rate and side-effects incidence of these trials was meta-analyzed.The publication bias was tested by funnel plot.Result Fifteen randomized clinical trials were included in the analysis.Pooled H.pylori eradication rate was 79.7%(95% CI: 77.1%~82.3%) and 69.5%(95% CI: 66.5%~72.5%) with and without combination of probiotics,respectively;the summary OR was 1.75(95% CI: 1.40~2.18);the total occurrence of side-effects was 27.7%(95% CI: 24.5%~30.9%) and 53.0%(95%CI: 49.4%~56.6%) in groups with and without probiotics,respectively;the summary OR was 0.35(95% CI: 0.21~0.60).Conclusion Probiotics supplement is effective in increasing the eradication rate during standard triple therapy for H.pylori eradication.Furthermore,probiotics show a positive impact on H.pylori therapy related side-effects.
出处 《中国微生态学杂志》 CAS CSCD 2012年第4期334-338,共5页 Chinese Journal of Microecology
关键词 幽门螺杆菌 微生态制剂 META分析 根除率 不良反应 Helicobacter pylori Probiotics Meta-Analysis Eradication Rate Side effects
  • 相关文献

参考文献21

  • 1GO M F.Review article:natural history and epidemiology of Helicobact-er pylori infection[J].Aliment Pharmacol Ther,2002,16(Suppl 1):3-15.
  • 2MEGRAUD F.H.pylori antibiotic resistance:prevalence,importance,and advances in testing[J].Gut,2004,53(9):1374-1384.
  • 3JAGUSZTYN KRYNICKA E K,GODLEW SKA R.New approaches forHelicobacter vaccine development-difficulties and progress[J].Pol JMicrobio,2008,57(1):3-9.
  • 4VALEUR N,ENGEL P,CARBAJAL N,et al.Colonization and immu-nomodulation by Lactobacillus reuteri ATCC 55730 in the human gas-trointestinal tract[J].Appl Environ Microbiol,2004,70(2):1176-1181.
  • 5ARMUZZI A,CREMONINI F,OJETTI V,et al.Effect of LactobacillusGG supplementation on antibioticassociated gastrointestinal side effectsduring Helicobacter pylori eradication therapy:a pilot study[J].Diges-tion,2001,63(1):1-7.
  • 6SYKORA J,VALEKOVK,AMLEROVJ,et al.Effects of a speciallydesigned fermented milk product containing probiotic Lactobacillus ca-sei DN-114 001 and the eradication of H.pylori in children:a prospec-tive randomized double-blind study[J].J Clin Gastroenterol,2005,39(8):692-698.
  • 7PARK S K,PARK D I,CHOI J S,et al.The effect of probiotics on He-licobacter pylori eradication[J].Hepatogastroenterology,2007,54(79):2032-2036.
  • 8BEKAR O,YILMAZ Y,GULTEN M.Kefir improves the efficacy andtolerability of triple therapy in eradicating Helicobacter pylori[J].J MedFood.2011,14(4):344-347.Epub 2010 Dec 27.
  • 9SZAJEWSKA H,ALBRECHT P,TOPCZEWSKA-CABANEK A.Ran-domized,double-blind,placebo-controlled trial:effect of LactobacillusGG supplementation on Helicobacter pylori eradication rates and sideeffects during treatment in children[J].J Pediatr Gastroenterol Nutr,2009,48(4):431-436.
  • 10DA SILVA MEDEIROS J A,GONALVES T M,BOYANOVA L,etal.Evaluation of Helicobacter pylori eradication by triple therapy plusLactobacillus acidophilus compared to triple therapy alone[J].Eur JClin Microbiol Infect Dis,2011,30(4):555-9.Epub 2011 Jan 5.

同被引文献81

  • 1罗宜辉,刘代华.益生菌用于幽门螺杆菌根除治疗的研究进展[J].医学信息(医学与计算机应用),2014,0(7):500-500. 被引量:3
  • 2陈淑萍,王磊,余建奎.益生菌联合三联疗法根除幽门螺杆菌的临床研究[J].中华临床感染病杂志,2012,5(2):98-100. 被引量:42
  • 3陈云华,汪春莲,谢云.幽门螺杆菌致病机制及益生菌防治作用的研究进展[J].世界华人消化杂志,2007,15(25):2690-2697. 被引量:52
  • 4Dunn BE,Cohen H,Blaser MJ.Helicobacter pylori.Clin Microbiol Rev 1997; 10: 720-741.
  • 5Malfertheiner P,Megraud F,O'Morain CA,Atherton J,Axon AT,Bazzoli F,Gensini GF,Gisbert JP,Graham DY,Rokkas T,El-Omar EM,Kuipers EJ.Management of Helicobacter pylori infection--the Maastricht IV/ Florence Consensus Report.Gut 2012; 61: 646-664.
  • 6Fuccio L,Zagari RM,Minardi ME,Bazzoli F.Systematic review: Helicobacter pylori eradication for the prevention of gastric cancer.Aliment Pharmacol Ther 2007; 25: 133-141.
  • 7Graham DY,Lu H,Yamaoka Y.A report card to grade Helicobacter pylori therapy.Helicobacter 2007; 12: 275-278.
  • 8Reid G,Jass J,Sebulsky MT,McCormick JK.Potential uses of probiotics in clinical practice.Clin Microbiol Rev 2003; 16: 658-672.
  • 9Oxman AD.Checklists for review articles.BMJ 1994; 309: 648-651.
  • 10Oxman AD,Guyatt GH.Validation of an index of the quality of review articles.J Clin Epidemiol 1991; 44: 1271-1278.

引证文献6

二级引证文献60

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部